Annual D&A
$12.02 M
+$8.26 M+219.79%
31 December 2022
Summary:
Eagle Pharmaceuticals annual depreciation & amortization is currently $12.02 million, with the most recent change of +$8.26 million (+219.79%) on 31 December 2022. During the last 3 years, it has risen by +$8.49 million (+239.85%). EGRX annual D&A is now at all-time high.EGRX Depreciation And Amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly D&A
$5.58 M
+$20.00 K+0.36%
30 June 2023
Summary:
Eagle Pharmaceuticals quarterly depreciation & amortization is currently $5.58 million, with the most recent change of +$20.00 thousand (+0.36%) on 30 June 2023. EGRX quarterly D&A is now -0.89% below its all-time high of $5.63 million, reached on 31 December 2022.EGRX Quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM D&A
$20.62 M
+$3.95 M+23.66%
30 June 2023
Summary:
Eagle Pharmaceuticals TTM depreciation & amortization is currently $20.62 million, with the most recent change of +$3.95 million (+23.66%) on 30 June 2023. EGRX TTM D&A is now at all-time high.EGRX TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EGRX Depreciation And Amortization Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +239.8% | +517.9% | +476.7% |
| 5 y5 years | +227.6% | +405.4% | +390.4% |
EGRX Depreciation And Amortization High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +239.8% | -0.9% | +517.9% | at high | +476.7% |
| 5 y | 5 years | at high | +244.3% | -0.9% | +4436.6% | at high | +642.3% |
| alltime | all time | at high | >+9999.0% | -0.9% | >+9999.0% | at high | >+9999.0% |
Eagle Pharmaceuticals Depreciation And Amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | $5.58 M(+0.4%) | $20.62 M(+23.7%) |
| Mar 2023 | - | $5.56 M(-1.2%) | $16.68 M(+38.7%) |
| Dec 2022 | $12.02 M(+219.8%) | $5.63 M(+46.2%) | $12.02 M(+61.2%) |
| Sept 2022 | - | $3.85 M(+135.7%) | $7.46 M(+65.4%) |
| June 2022 | - | $1.63 M(+80.0%) | $4.51 M(+19.6%) |
| Mar 2022 | - | $908.00 K(-14.9%) | $3.77 M(+0.3%) |
| Dec 2021 | $3.76 M(+6.3%) | $1.07 M(+18.2%) | $3.76 M(+5.1%) |
| Sept 2021 | - | $903.00 K(+1.0%) | $3.58 M(+1.2%) |
| June 2021 | - | $894.00 K(-0.2%) | $3.54 M(+0.5%) |
| Mar 2021 | - | $896.00 K(+1.5%) | $3.52 M(-0.6%) |
| Dec 2020 | $3.54 M(+1.3%) | $883.00 K(+2.4%) | $3.54 M(+27.4%) |
| Sept 2020 | - | $862.00 K(-1.6%) | $2.78 M(-8.0%) |
| June 2020 | - | $876.00 K(-4.5%) | $3.02 M(-7.8%) |
| Mar 2020 | - | $917.00 K(+645.5%) | $3.28 M(-6.2%) |
| Dec 2019 | $3.49 M(-4.9%) | $123.00 K(-88.9%) | $3.49 M(-17.0%) |
| Sept 2019 | - | $1.10 M(-2.5%) | $4.21 M(+6.8%) |
| June 2019 | - | $1.13 M(-0.1%) | $3.94 M(+3.8%) |
| Mar 2019 | - | $1.13 M(+35.5%) | $3.79 M(+3.3%) |
| Dec 2018 | $3.67 M(-2.1%) | $836.00 K(+0.1%) | $3.67 M(-3.1%) |
| Sept 2018 | - | $835.00 K(-15.5%) | $3.79 M(-2.6%) |
| June 2018 | - | $988.00 K(-2.3%) | $3.89 M(+1.1%) |
| Mar 2018 | - | $1.01 M(+5.9%) | $3.85 M(+2.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2017 | $3.75 M(+135.8%) | $955.00 K(+1.9%) | $3.75 M(+8.3%) |
| Sept 2017 | - | $937.00 K(-1.1%) | $3.46 M(+19.8%) |
| June 2017 | - | $947.00 K(+4.3%) | $2.89 M(+28.2%) |
| Mar 2017 | - | $908.00 K(+36.1%) | $2.25 M(+41.8%) |
| Dec 2016 | $1.59 M(+1318.8%) | $667.00 K(+82.2%) | $1.59 M(+58.4%) |
| Sept 2016 | - | $366.00 K(+17.3%) | $1.00 M(+55.3%) |
| June 2016 | - | $312.00 K(+27.9%) | $646.00 K(+87.8%) |
| Mar 2016 | - | $244.00 K(+201.2%) | $344.00 K(+207.1%) |
| Dec 2015 | $112.00 K(+7.7%) | $81.00 K(+800.0%) | $112.00 K(+154.5%) |
| Sept 2015 | - | $9000.00(-10.0%) | $44.00 K(-23.1%) |
| June 2015 | - | $10.00 K(-16.7%) | $57.20 K(-17.7%) |
| Mar 2015 | - | $12.00 K(-7.7%) | $69.50 K(-19.1%) |
| Dec 2014 | - | $13.00 K(-41.4%) | $85.90 K(-17.3%) |
| Sept 2014 | $104.00 K(-23.0%) | $22.20 K(-0.4%) | $103.90 K(-6.7%) |
| June 2014 | - | $22.30 K(-21.5%) | $111.40 K(-3.9%) |
| Mar 2014 | - | $28.40 K(-8.4%) | $115.90 K(+2.3%) |
| Dec 2013 | - | $31.00 K(+4.4%) | $113.30 K(-16.1%) |
| Sept 2013 | $135.00 K(-43.8%) | $29.70 K(+10.8%) | $135.00 K(+28.2%) |
| June 2013 | - | $26.80 K(+3.9%) | $105.30 K(+34.1%) |
| Mar 2013 | - | $25.80 K(-51.0%) | $78.50 K(+49.0%) |
| Dec 2012 | - | $52.70 K | $52.70 K |
| Sept 2012 | $240.00 K | - | - |
FAQ
- What is Eagle Pharmaceuticals annual depreciation & amortization?
- What is the all time high annual D&A for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals quarterly depreciation & amortization?
- What is the all time high quarterly D&A for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals TTM depreciation & amortization?
- What is the all time high TTM D&A for Eagle Pharmaceuticals?
What is Eagle Pharmaceuticals annual depreciation & amortization?
The current annual D&A of EGRX is $12.02 M
What is the all time high annual D&A for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high annual depreciation & amortization is $12.02 M
What is Eagle Pharmaceuticals quarterly depreciation & amortization?
The current quarterly D&A of EGRX is $5.58 M
What is the all time high quarterly D&A for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high quarterly depreciation & amortization is $5.63 M
What is Eagle Pharmaceuticals TTM depreciation & amortization?
The current TTM D&A of EGRX is $20.62 M
What is the all time high TTM D&A for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high TTM depreciation & amortization is $20.62 M